Takeda Pharmaceutical Company Ltd. / Tesaro Inc.

Ovarian Cancer

22K US cases/yr

Disease Overview

Ovarian cancer is the deadliest gynecologic malignancy, frequently diagnosed at advanced stage because early disease is asymptomatic. Most cases are high-grade serous epithelial tumors and roughly 15-20% harbor germline or somatic BRCA1/2 mutations or broader homologous-recombination deficiency (HRD), making them sensitive to PARP inhibition. Standard of care is debulking surgery plus platinum-based chemotherapy with growing use of PARP inhibitor maintenance.

Competitive Landscape

By July 2017 the PARP inhibitor class had three approved players in ovarian cancer: AstraZeneca/Merck's Lynparza (olaparib, first approved 2014), Clovis's Rubraca (rucaparib, December 2016), and TESARO's Zejula (niraparib, March 2017 — the first FDA-approved PARP for use regardless of BRCA status in platinum-sensitive recurrent maintenance). Niraparib launched into a head-to-head positioning battle on the back of NOVA trial data and quickly became the most frequently prescribed PARP in the US, per analyst commentary captured in Xconomy. Takeda's $100M upfront for Japan/Asia-Pacific rights validated niraparib's commercial trajectory and, as Jefferies noted, gave TESARO cash runway into 2018 while signaling 'unlikely near-term buyout' (Xconomy 2017-07-27) — a thesis later contradicted when GSK acquired TESARO for $5.1B in December 2018. The deal mattered because it secured Japan rights for a Western-discovered PARP at a time when Takeda was rebuilding its oncology franchise, and because it provided non-dilutive capital that funded niraparib's expansion into first-line maintenance (PRIMA, NEJM 2019). Subsequent class headwinds — voluntary withdrawal of late-line BRCA-mutated indications across all three PARPs (OncLive 2022) — reshaped competitive positioning toward first-line maintenance. [https://www.biopharmadive.com/news/tesaro-lands-licensing-supply-agreements-for-zejula/448066/]